Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Digoxin is effective, but is it safe?

F I Marcus1

  • 1University of Arizona College of Medicine, Tucson.

Cardiovascular Drugs and Therapy
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Digitalis effectively treats heart failure symptoms and improves function, but its safety after myocardial infarction is questionable, potentially increasing mortality. Careful consideration of digitalis administration is crucial.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Familial Mahaim syndrome.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·2001
Same author

Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials.

Circulation·2001
Same author

Electrocardiographic features of inherited diseases that predispose to the development of cardiac arrhythmias, long QT syndrome, arrhythmogenic right ventricular cardiomyopathy/dysplasia, and Brugada syndrome.

Journal of electrocardiology·2001
Same author

Moving toward a new definition of acute myocardial infarction for the 21st century: status of the ESC/ACC consensus conference. European Society of Cardiology and American College of Cardiology.

Journal of electrocardiology·2001
Same author

Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. European Society of Cardiology and the Scientific Council on Cardiomyopathies of the World Heart Federation.

Journal of cardiovascular electrophysiology·2000
Same author

Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation.

Circulation·2000
Same journal

GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease.

Cardiovascular drugs and therapy·2026
Same journal

Methodological Considerations in Evaluating Plaque Stabilization in Patients with High Lipoprotein(a).

Cardiovascular drugs and therapy·2026
Same journal

Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Impact of Nitric Oxide Metabolites On Early Perioperative Biochemical Changes and Postoperative Complications in High-BMI Patients Undergoing On-Pump CABG: an Exploratory Observational Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.

Cardiovascular drugs and therapy·2026
Same journal

Cardiovascular Genetic Epidemiology in the Genome-Wide Era: From Association Discovery to Mechanistic Dissection and Clinical Translation.

Cardiovascular drugs and therapy·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Digitalis has demonstrated efficacy in managing congestive heart failure symptoms and improving cardiac function over the past 15 years.
  • Clinical trials consistently show reduced hospitalizations for heart failure patients treated with digitalis.

Purpose of the Study:

  • To evaluate the safety profile of digitalis, specifically concerning mortality rates.
  • To investigate the association between digitalis use and increased mortality following acute myocardial infarction.

Main Methods:

  • Review of double-blind, placebo-controlled clinical trials.
  • Analysis of experimental data and clinical evidence.
  • Statistical adjustment for predictor covariants and comorbidity.

Related Experiment Videos

Main Results:

  • Digitalis use is linked to decreased heart failure symptoms, reduced hospitalizations, and improved cardiac function.
  • Evidence suggests a potential increase in mortality associated with digitalis, particularly within the first two years post-myocardial infarction.
  • This increased mortality risk persists even after statistical adjustments for comorbidities.

Conclusions:

  • The safety of digitalis, especially after acute myocardial infarction, remains a significant concern.
  • Physicians must carefully weigh the indications for prescribing digitalis in patients with a history of myocardial infarction.
  • Enhanced patient surveillance is necessary during chronic digitalis therapy.